Medical/Pharmaceuticals

MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents

SHENZHEN, China, April 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, celebrates its 10th anniversary, a decade marked by breakthroughs that have helped transform genomics into a scalable, d...

2026-04-13 16:05 4303

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...

2026-04-13 14:24 4176

AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer

TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American A...

2026-04-13 12:00 4031

Telix and Regeneron Announce Strategic Radiopharma Collaboration

* Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. * Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/developme...

2026-04-13 06:57 5352

Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management

SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF), Sinocare presented its latest advancements under the theme "Leading Digital Healthcare For Global Health." Bringing together cutting-edge technologies, integrated solutions, and strategic partn...

2026-04-11 18:30 5550

SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH

NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...

2026-04-11 16:20 4533

Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development

* Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the s...

2026-04-10 20:00 5476

Ceva Animal Health appoints Sébastien Huron as Deputy Chief Executive Officer

LIBOURNE, France, April 10, 2026 /PRNewswire/ -- Ceva Animal Health, the world's fifth largest animal health company, majority-owned by its management team, today announces the appointment of Sébastien Huron as Deputy Chief Executive Officer, effective immediately. This move forms part of a broad...

2026-04-10 14:00 4863

NovogeneAIT Genomics Appointed as Service Provider to Advance Large-Scale Proteomics for PRECISE-SG100K Cohort in Singapore

SINGAPORE, April 10, 2026 /PRNewswire/ -- NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K  proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by...

2026-04-10 12:44 6368

Tairex Launches Virtual Consultation Room, Setting A New Paradigm for AI Medical Services

BEIJING, April 10, 2026 /PRNewswire/ -- Wuxi Tairex Technology Co. Ltd. ("Tairex" or the "Company") today announced the launch of the Virtual Consultation Room for Tairex Agent Hospital, now open to doctors and medical students. Built on Tairex Agent Hospital, a virtual medical world centered on...

2026-04-10 11:28 5828

ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406

SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza infection, follo...

2026-04-10 09:00 6322

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

* Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investme...

2026-04-10 08:30 6170

Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...

2026-04-10 08:00 4999

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its...

2026-04-10 08:00 6679

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company's resubmitted New Drug Application (NDA) for TLX101-Px[1],...

2026-04-10 06:50 6187

NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan

SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has entered into an exclusive distribution agreement in Japan with Asahi Intecc Co., Ltd., a global medical device compan...

2026-04-09 21:00 4784

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the ...

2026-04-09 21:00 6228

Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)

Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care. PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leadi...

2026-04-09 20:03 4956

GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era

The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030. PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies...

2026-04-09 20:00 4673

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer

SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been ...

2026-04-09 19:55 5649
1 ... 15161718192021 ... 650